Fujimoto Pharmaceutical Corp.

Egetis has secured a green light in Europe for its ultra rare disease drug Emcitate and the Swedish biotech is looking to hit the ground running with a first launch in the next few months on its own.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Menarini, SciClone Will Partner On

SymBio Pharmaceuticals has begun a Phase II trial in Japan with its lead product bendamustine for the treatment of the refractory and relapsed forms of multiple myeloma. The Japanese venture initiated

Wyeth/Pfizer's infused mTOR kinase inhibitor, Torisel (temsirolimus), has been recommended for approval in Japan for the treatment of advanced renal cell carcinoma (RCC). The product stands to become